Spirepoint Private Client’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Spirepoint Private Client's VRTX Position: Q2 2026 in Review
Spirepoint Private Client opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 433 shares worth $215K. The stake represents 0.02% of the portfolio and ranks #317 among its holdings. This is a return to the name: Spirepoint Private Client previously reported a position in VRTX as recently as Q4 2025.
Spirepoint Private Client first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $228K in Q4 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Spirepoint Private Client held 433 shares of Vertex Pharmaceuticals worth $215K as of Q2 2026.
- Vertex Pharmaceuticals was a new Spirepoint Private Client position in Q2 2026.
- Vertex Pharmaceuticals made up 0.02% of Spirepoint Private Client's portfolio in Q2 2026, its #317 holding.
- Spirepoint Private Client first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
- Spirepoint Private Client's Vertex Pharmaceuticals position peaked at $228K in Q4 2025.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Spirepoint Private Client's 13F filing for Q2 2026, filed 5 Aug 2026.